NCT05898256

Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

A Single-arm, Multicenter, Phase II Study Evaluating the Efficacy and Safety of Cadonilimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Guangxi Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study is a single-arm, multicenter clinical study to evaluate the efficacy and safety of Cadonilimab in combination with gemcitabine/cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.

Conditions

• Nasopharyngeal Carcinoma
• Immune Checkpoint Inhibitors

Interventions

Type	Name	Description
DRUG	Cadonilimab	10mg/kg administered intravenously (IV)
DRUG	Gemcitabine	1 g/m2, administered as an IV infusion within 30 minutes
DRUG	Cisplatin	80 mg/m2, administered as an IV infusion over 4 hours

Timeline

• Start date: 2023-08-01
• Primary completion: 2024-07-31
• Completion: 2026-07-31
• First posted: 2023-06-12
• Last updated: 2023-06-12